EGFR and non-small cell lung carcinoma: While an extensive analysis of TMB has not been performed across a large set of driver variations in NSCLC, a study has shown that EGFR-variant NSCLC has markedly lower TMB compared with EGFR-wildtype NSCLC.11 Lower TMB has been shown in multiple studies to predict worse outcomes on immune checkpoint inhibitors, including in the CheckMate 227 trial.12,13 This is possibly because of fewer immunogenic targets.